Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515865 | 0.94 | L3MBTL1 (0.49) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL6511742 | 0.93 | PAM (0.51) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL2457851 | 0.93 | SLC7A5 (0.47) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL3620906 | 0.93 | PAM (0.51) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL1401401 | 0.93 | L3MBTL1 (0.46) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL2630609 | 0.91 | PPARA (0.51) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL8150062 | 0.91 | L3MBTL1 (0.45) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL1810195 | 0.91 | L3MBTL1 (0.45) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL5948910 | 0.91 | FOLH1 (0.46) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 | |
| SCHEMBL31074140 | 0.91 | CYP4F2 (0.48) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549010-A | Preparation and application of compound with AMPK agonistic activity and prodrug thereof | 中国科学院上海药物研究所 | 2021-10-26 | — | — | CN | disclosed |
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | PURDUE PHARMA L.P. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | PURDUE PHARMA L.P. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| EP-2782570-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20180370971-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-12-27 | — | — | US | disclosed |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-05-31 | — | — | US | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050222128-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| WO-2005092860-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| US-20050215542-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| EP-1574501-A1 | Quinolinone derivatives, pharmaceutical compositions containing them and their use | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080313-A2 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | PFIZER INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | L3MBTL1 4146/4885SMN1; SMN2 4375/4885ALDH1A1 639/4885 |
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | QDPR, P2RX4, P2RX5 | L3MBTL1 4667/4885SMN1; SMN2 1041/4885ALDH1A1 800/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | L3MBTL1 4146/4885SMN1; SMN2 4375/4885ALDH1A1 639/4885 |
| US-20050182091-A1 | For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal | LTC4S, LTB4R2, LTB4R | L3MBTL1 2316/4885SMN1; SMN2 3194/4885ALDH1A1 130/4885 |
| US-20180370971-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | P2RX4, OPRK1, QDPR | L3MBTL1 2731/4885SMN1; SMN2 571/4885ALDH1A1 709/4885 |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, OPRK1, QDPR | L3MBTL1 2731/4885SMN1; SMN2 571/4885ALDH1A1 709/4885 |
| US-20050171147-A1 | Sulfonamide derivatives for the treatment of diseases | SULT2A1, STS, SULT1A1 | L3MBTL1 4767/4885SMN1; SMN2 697/4885ALDH1A1 178/4885 |
| US-20050215542-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, EPX | L3MBTL1 3847/4885SMN1; SMN2 1244/4885ALDH1A1 152/4885 |
| US-20050222128-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, CYP11B2 | L3MBTL1 3963/4885SMN1; SMN2 1291/4885ALDH1A1 128/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | L3MBTL1 4748/4885SMN1; SMN2 1653/4885ALDH1A1 160/4885 |
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | P2RX4, OPRK1, QDPR | L3MBTL1 2731/4885SMN1; SMN2 571/4885ALDH1A1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.